Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss
Read Article
Compared to in-person physical therapy, claims data revealed lower healthcare utilization and spending for patients who used Omada’s programs for musculoskeletal conditions
Read Article
PROMISE TO MAP is Omada's approach to build safety and security into AI-powered products.
Read Resource
Error - something went wrong!
Become an Omada Insider, subscribe to our monthly newsletter
Thank you!
Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025.
Read Article
Meet Heather, a real Omada member from Atlanta, GA in the Omada for Prevention & Weight Health program with the embedded GLP-1 enhanced care track. Here's her journey.
Watch Video
Niki got personalized support and accountability from her coach to make small changes to build lasting healthy habits. Here's her journey.
Watch Video
She has multiple chronic conditions and was able to get support from her entire care team to make healthy changes. Here's her journey.
Watch Video
Christina not only got support to make small changes to build healthy habits but with the support Christina got between visits, she was able to lower her medication dosage. Here’s her journey.
Watch Video
In this ~2-minute video, Omada's Senior Director of Clinical and Translational Research, Sarah Linke, summarizes findings of our July 2025 clinical white paper on GLP-1 Persistence
Read Article
Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results.
Read Article
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises
Read Article
Medication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.
Read Resource
Omada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a public offering price of $19.00 pe
Read Article
Omada Health announces its initial public offering, offering 7.9 million shares at $18–$20 each, and plans to list on Nasdaq under the ticker symbol “OMDA.”
Read Article
On May 20, 2025, Omada Horizon Day showcased how our AI-powered innovations are transforming member relationships with food. Watch the recording of our Spring 2025 product innovation unveiling!
Watch Video
Become an Omada Insider, subscribe to our monthly newsletter.
Sign me upWhy GLP-1s are not a silver bullet for obesity, the role of behavior change support teams and how they complement obesity medicine specialists, and how providers can achieve optimal outcomes.
Read Article
This edition covers the imminent expansion of GLP-1s on a worldwide scale, the global burden and prevalence of obesity and chronic diseases, and the clinical and economic realities of GLP-1 expansion.
Read Article
Self-efficacy is key for long-term GLP-1 weight loss success. Find out how Omada’s Enhanced GLP-1 Care Track helps members achieve sustainable weight health.
Read Article
This analysis found that lifestyle-focused virtual health program to support cardiometabolic disease management may lead to meaningful reductions in high-cost acute care encounters.
Read Article
This analysis evaluated demographic & clinical characteristics of adults without diabetes who reported recent use of GLP-1s for weight loss while enrolled in a digital weight management program.
Read Article
Loading More...
